So if we then assume that Tolga in addition to his already acquired 13,086,727 shares ( 5.29%) are then bolted onto Tranche 1. ( per below ) , he would then have potentially 78,608,962 or 17.23% of the company or just afew percentages below the takeover threshold 20%.....Even he is more likely to be the ' key ' stakeholder being allocated the 28,434,177 under ASX listing capacity 7.1A 10% , he would still have close to 10% ( convenient blocking stake ) with his allocation of corresponding options.....Ya so definitely some serious ' jostling ' in among the Top 20 and ' insider ' control of the company in my opinion......Tranche 1 will comprise 65,522,235 Shares at 1.1 cents per Share to raise $720,744 (before costs), to beissued under the Company’s available placement capacity as follows:o 37,088,057 Shares under ASX Listing Rule 7.1; ando 28,434,177 Shares ASX Listing Rule 7.1A; andTranche 2 will comprise 73,795,947 Shares at 1.1 cents per Share to raise $811,755 (before costs), to beissued subject to shareholder approval.
- Forums
- ASX - By Stock
- RGL
- Ann: Becoming a substantial holder Tolga Kumova
Ann: Becoming a substantial holder Tolga Kumova, page-37
-
-
- There are more pages in this discussion • 281 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RGL (ASX) to my watchlist
|
|||||
Last
0.7¢ |
Change
0.001(16.7%) |
Mkt cap ! $8.467M |
Open | High | Low | Value | Volume |
0.8¢ | 0.8¢ | 0.7¢ | $259.8K | 34.17M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 4299526 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 6686426 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 4299526 | 0.007 |
22 | 7999263 | 0.006 |
37 | 15681851 | 0.005 |
13 | 7299444 | 0.004 |
11 | 13946667 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 6686426 | 13 |
0.009 | 6945497 | 15 |
0.010 | 3739626 | 9 |
0.011 | 3192850 | 7 |
0.012 | 185635 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
RGL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online